Phase 3 Study Comparing Bedaquiline and Rifampicin Combination to Standard Rifampicin for Preventing Leprosy
Led by Institute of Tropical Medicine, Belgium · Updated on 2026-05-19
124000
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new approach to prevent leprosy in people living near someone recently diagnosed with the disease. This phase 3 randomized study compares two treatments a combination of bedaquiline and rifampicin BE-PEP versus the World Health Organizations standard single-dose rifampicin SDR-PEP. The goal is to assess which method better reduces the risk of developing leprosy and lowers the overall number of cases over time.
Participants will be assigned to one of two groups. In the intervention group, BE-PEPbedaquiline at 400 or 800 mg depending on weight combined with rifampicin at 10 mgkgis given to individuals living within 100 meters of an index case, with a repeat dose after four weeks for household contacts. The comparison group receives the standard single dose of rifampicin at 10 mgkg. If more than half the village is eligible, the entire village is included. Treatment delivery uses specific dosage forms of rifampicin and bedaquiline, and the study started providing BE-PEP in 2023, with follow-up planned through 2026.
During the study, participants are monitored for leprosy development and possible side effects such as nausea, headache, dizziness, or skin reactions up to 30 days after treatment. Researchers collect skin biopsies from leprosy patients to check for drug resistance using molecular tests and monitor tuberculosis patients for similar resistance patterns. The main outcome measured is the rate of leprosy cases between the two groups over about four years, alongside a village-level impact assessment. The study aims to provide a safe and effective prevention strategy and support future national guideline updates.
CONDITIONS
Brief Title
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Research Team
C
Carolien Hoof
N
Natacha Herssens
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Living in one of the study clusters on Anjouan or Mohéli in good health
Aged 2 years or older (children 2-4 years or weighing less than 20 kg will receive rifampicin only)
Able and willing to give informed consent for leprosy and tuberculosis screening and prophylaxis
You will not qualify if you...
Signs of active leprosy
Signs of active pulmonary tuberculosis (cough lasting 2 weeks or more without a negative TB test)
Signs of active extra-pulmonary tuberculosis (bluish-red nodules on lymph nodes, bones, joints, or cervical glands with discharge)
Use of rifampicin or bedaquiline in the last 2 years
Suspected or confirmed pregnancy or breastfeeding
Use of medications not on the safe list within the last 3 weeks before study start (for bedaquiline only)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Treatment
Duration - Repeated dose for household contacts after four weeks
Participants receive post-exposure prophylaxis with either BE-PEP (bedaquiline combined with rifampicin) or standard SDR-PEP (single dose rifampicin) to prevent leprosy.
1 to 2 visits depending on household contact status
Long-term Monitoring
Duration - Up to approximately 4 years
Participants are followed up to assess leprosy incidence, monitor potential adverse events, and evaluate drug resistance until study completion.
Periodic visits over the follow-up period until 2026
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Evaluating Ultrasound-Guided PCR Testing of Ulnar Nerve Aspirate for Diagnosing and Monitoring Leprosy
Phase 3 Study Comparing Bedaquiline and Rifampicin Combination to Standard Rifampicin for Preventing Leprosy
Testing Metformin Added to Standard Multidrug Treatment for Multibacillary Leprosy in Adults
A Randomized, Double-Blind Phase 2 Trial in Indonesia
Studying Rifampin Treatments and a New Test for Detecting Leprosy Infection
in People Exposed to Leprosy in Bangladesh
Study of Rab 32 Gene Variations and Their Impact on Leprosy Treatment Using Multi-Drug Therapy with Dapsone, Clofazimine, and Rifampicin
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts.
Assoumani Younoussa, Said Nourdine Samidine, Auke T Bergeman...